ENTREPRENEURSHIP

PROJECT:
BIOCON
SUBMITTED TO- SUBMITTED BY-
DR. ABHA AMAN BAJAJ
237/15
BCOM LLB(HONS.)
KIRAN MAZUMDAR SHAW
 Early life
• Born on March 23 , 1953 in Bangalore Gujarati-Brahmin middle class
family

• Schooling at Bishop Cotton Girls School & Mount Carmel College at

Bangalore

• B.Sc in Zoology from Bangalore University

• Qualified as a master brewer from Ballarat Universtiy, Australia

• Founded Biocon as an enzyme-manufacturer, aged 25, out of her
garage with Rs. 10,000 seed money
• In 2004, she became India’s Richest Woman
Personal life
• Kiran Mazumdar Shaw is married to John Shaw, a
Scotsman and Indophile.
• John Shaw headed a leading textiles MNC, Madura
Coats from 1991 to 1998 as CMD.

• Currently, John Shaw is Vice-Chairman of Biocon,

Ltd.
• She has huge collections of paintings and other art
works.
• She has also written a coffee table book named
“Ale & Arty”- the story of Beer.
 Starting
• Trainee brewer in Carlton and United Breweries,
Melbourne.
• Trainee maltster at Barrett Brothers and Burston ,Australia.
• Technical consultant at Jupiter Breweries Limited, Calcutta
and as a technical manager at Standard Maltings Corporation,
Baroda between 1975 and 1977.
 THE JOURNEY BEGINS
• In 1978, she joined Biocon Biochemicals Limited, of Cork, Ireland as a Trainee Manager.
• In 1978 itself, she started Biocon in he garage in Bangalore with a capital of Rs. 10,000.

• Within a year, Biocon became the first Indian company to manufacture and export enzymes to
USA and Europe.
• In 1990, she upgraded Biocon’s in-house research program, based on a proprietary solid substrate
fermentation technology.
• The commercial success of this program led to a three-fold expansion by 1996 and Biocon entered
the biopharmaceuticals and statins segments

• In 1998, when Unilever agreed to sell its shareholding in Biocon to the Indian promoters, Biocon
became an independent entity.
 BIOCON INDIA
• Biocon Limited (BSE: 532523) is an Indian biopharmaceutical company based in Bangalore, India.The
Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120
countries across the globe, including the developed markets of the United States and Europe .It also
manufactures novel biologics, as well as, biosimilar insulin's and antibodies, which are sold in India as
branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in
several emerging markets. In research services, Syngene International Limited (Syngene), a publicly
listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and
development services.
• Biocon and Syngene together employ about 9200 personnel including biologists, chemists, medical
practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists and general
administrators.[
• In 1979, Biocon became the first Indian company to manufacture and export enzymes
to USA and Europe.

• Biocon is a research driven , global healthcare company with a strong matrix of

capabilities along the biopharmaceutical value chain.

• They believe in strategic licensing partnerships which rapidly provide wider global
access and greater market penetration.
 SUCCESS OF BIOCON
• Biocon India Group story began in 1978.
• In 1989, Unilever acquired 30% stake.
• In 1997, Unilever sold their stake to ICI.
• Eventually John Shaw purchased the entire shareholding from ICI.
• In 1994, Syngene International was established to carry out drug based
contract research.
• In 2000, Clinigene International was started to conduct longitudinal clinical
studies.
• In 2003, Biocon became the first company worldwide to develop human insulin on a
Pichia express system.
• Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO.
Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only
the second Indian company to cross the $1 billion mark on the first day of listing.
• She entered into more than 2,200 high-value R&D licensing and other deals within the
pharmaceuticals and bio-pharmaceutical space between 2005 & 2010
• In 2007 leading US trade publication, Med Ad News, ranked Biocon as the 20th leading
biotechnology companies in the world and the 7th largest biotech employer in the
world..
• In 2009 received Bio Singapore Asia Pacific Biotechnology Award for Best Listed
Company .It has Asia’s largest insulin and statin facilities as also the largest
perfusion-based antibody production facilities.
• Between 2005 and 2010 Biocon entered into more than 2,200high-value R&D
licensing and other deals within the pharmaceuticals and bio-pharmaceutical space
and helped Biocon expand its global footprint to emerging and developed markets
through acquisitions, partnerships and in-licensing.
• On November 2012, Biocon become the only Asian Company to Feature in the
Global Top 20 Bio Pharma Employers, by Science Magazine.
 PRODUCTS AND SERVICES
OFFERED BY BIOCON
• BIOPHARMACEUTICALS
The Indian Pharmaceutical company Biocon is capable to meet the country's demand for every drug. The
manufacturing units within the country are meeting about 70% of the country's drug requirements. The drug
production sector is equipped with technology and researched knowledge base. The company produces drugs
worth rupees 18000 crores and is growing at 9 percent every year. It offers quality products with internationally
accepted quality standards. There are many production units in India with products sold at competitive lower
prices than international drug prices.They make drugs for Diabetology, Nephrology,Oncology, Cardiology
• ENZYMES

Biocon is India's largest producer and exporter of enzymes. It manufactures and

markets a broad range of industrial enzymes, food additives and process aids. Biocon is
the first enzyme company globally to receive the ISO 9001 accreditation. Enzymes
manufactured by Biocon are: Amylases, Cellulases , Catalase , Lipases, Glucanases ,
Phytases , Proteases, and Pectinases .

• CLINICAL RESEARCH
Biocon subsidiary offers global biotechnology and pharmaceutical majors strong
clinical trial services, regulatory and laboratory capabilities for clinical drug
development. Its value added services include patient registries and clinical
databases in diabetes, lipidemia , oncology, cardiovascular diseases.
• CUSTOM RESEARCH
Biocon subsidiary conduct high value R&D in early stage drug discovery and
development for a diverse global companies.
 LEADERSHIP STYLE OF
KIRAN MAZUMDAR SHAW
• Kiran Mazumdar Shaw is a transformation leader .She had a Vision of her
own and she is an individualised type. She never follows what others do or
never cares
about what others think.

• Kiran Mazumdar Shaw inspires her team with a shared vision of the future.

• Divides the responsibilities amongst their team. Focussed more on R&D and
innovative strategy to produce new products .
 ACHIEVEMENTS OF
BIOCON
• Set up in 1978, Biocon is India's first biotech company.
• First Indian biotech company to receive US funding for proprietary technologies (1989)
• Sets up India's first clinical research organisation, Clinigene (2000)
• First Indian company to be approved by USFDA for the manufacture of lovastatin, a cholesterol-lowering molecule (2001)
• First company worldwide to develop human insulin on a Pichia expression system (2003)
• Launches India’s first cancer drug, BIOMAb EGFR (2006)
• First Indian company to manufacture and export enzymes to USA and Europe.
• India’s largest producer and exporter of enzymes.
• Releases country’s first 24-hour diabetes drug, Glargine (2009)
• First biotech company to receive ISO 9001 certification in India.
• Syngene is country’s first custom research company in drug discovery.
• First Indian Company to get a USFDA approval for a biosimilar (2017)
 CONTROVERSIES
• Air and water pollution in Hebbagodi in Bangalore.

-Death of fishes because of chemical effluent .

- People were suffering from skin disease, headache, kidney failure.

• Allegedly violate certain norms of manufacturing Methylcobalamin.

- Obtained license from the Karnataka government to manufacture the drug in seven stages
- But during inspection found that the company is importing the drug from china.
 PHILANTHROPIC ACTIVITIES
• The Biocon Foundation is involved in numerous health and education outreach programs to benefit
the economically weaker sections of Indian society

• In 2004, she started the Biocon Foundation to conduct health, education, sanitation, and environment
programs for the benefit of the economically weaker sections of society. The Foundation’s micro-
health Insurance program has an enrolment of 70,000 rural members

• She helped establish a 1,400-bed cancer care centre at the Narayana Health City campus at
Boommasandra, Bangalore, Mazumdar Shaw Cancer Centre.

• In collaboration with McMillan India Limited and teacher Prathima Rao, Mazumdar-Shaw has
supported development and use of a basic mathematics textbook, introduced in Kannada schools in
2006
 AWARDS AND HONOURS
• Mazumdar-Shaw is a member of the board of governors of the Indian School of Business and a past
member of the board of governors of the Indian Institute of Technology Hyderabad.

• ET Businesswoman of the Year, Best Woman Entrepreneur(2004)

• Mazumdar-Shaw is the recipient of several international awards including the Othmer Gold
Medal (2014).

• Ernst & Young's Entrepreneur of the Year Award for Life Sciences(2002).

• Indian Chamber of Commerce Lifetime Achievement Award (2005).

• Nikkei Asia Prize, 2009 for Regional Growth.

THANKYOU